Blog
RSS FeedPosted by Michael Wonder on 08 Jun 2022
TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios
8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...
Posted by Michael Wonder on 02 Jun 2022
TLV reconsiders subsidy of the IL-17 and IL-23 inhibitors
2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...
Posted by Michael Wonder on 25 May 2022
Health economic assessment of Trodelvy in advanced triple negative breast cancer
23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan). ...
Posted by Michael Wonder on 18 May 2022
TLV reconsiders subsidy of CGRP inhibitors
18 May 2022 - TLV has started a review of the CGRP inhibitors. ...
Posted by Michael Wonder on 17 May 2022
Health economic assessment of Xevudy for the treatment of COVID-19
17 May 2022 - TLV has produced a health economic assessment for the regions for the drug Xevudy (sotrovimab). ...
Posted by Michael Wonder on 16 May 2022
Tepmetko is granted a temporary subsidy
16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Blenrep in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin). ...
Posted by Michael Wonder on 26 Apr 2022
Health economic assessment of Leqvio in the treatment of high LDL cholesterol and mixed lipid disorders
26 April 2022 - The Swedish Dental and Pharmaceutical Benefits Agency has undertaken a health economic assessment of Leqvio (inclisiran) for ...
Posted by Michael Wonder on 19 Mar 2022
Final reconciliation of savings from side agreements for the full year 2021
18 March 2022 - TLV has presented the final reconciliation to the government of the outcome of the rebates in ...
Posted by Michael Wonder on 23 Feb 2022
Annual report 2021: more Government assignments and increased EU cooperation on TLV
23 February 2022 - In 2021, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reported a number of urgent government assignments ...
Posted by Michael Wonder on 12 Feb 2022
Health economic assessment of Jemperli in endometrial cancer
11 February 2022 - TLV has produced a health economic assessment for the regions for the drug Jemperli (dostarlimab) which is ...
Posted by Michael Wonder on 11 Feb 2022
Health economic assessment of Adakveo for the treatment of sickle cell anaemia
11 February 2022 - Adakveo is used to prevent recurrent so-called vaso-occlusive crises in patients from 16 years of age who ...
Posted by Michael Wonder on 07 Feb 2022
Health economic assessment of Opdivo in cancer of the oesophagus or upper gastro-intestinal tract
7 February 2022 - TLV has produced a health economic assessment for the regions for Opdivo (nivolumab). ...
Posted by Michael Wonder on 03 Feb 2022
Weak krona exchange rates result in lower drug prices
3 February 2022 - The price of medicines in Sweden has fallen compared with other countries and is among the lowest ...
Posted by Michael Wonder on 27 Jan 2022
The price of cystic fibrosis drugs is still too high
27 January 2022 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, has decided that Kaftrio and Kalydeco for cystic fibrosis ...